Follow Skye Bioscience, Inc.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
4 Stories, 3 about Skye Bioscience, Inc. 11 approved Program 0 Registered trials 10-Q Nov 13 Latest SEC filing Nov 12 Latest story
Timeline 3 Pipeline 1 Trials 0
Pipeline by stage
Approved 1
Details
Headquarters San Diego, CA Incorporated Nevada Industry Pharmaceutical Preparations Formerly Emerald Bioscience, Inc. (to 2021); Nemus Bioscience, Inc. (to 2019); LOAD GUARD LOGISTICS, INC. (to 2014); LOAD GUARD TRANSPORTATION, INC. (to 2012) Also known as Emerald Bioscience, Inc., LOAD GUARD LOGISTICS, INC., LOAD GUARD TRANSPORTATION, INC., Nemus Bioscience, Inc., SKYE How the company describes itself Skye Bioscience develops nimacimab, a negative allosteric modulating antibody that peripherally inhibits the CB1 receptor for weight loss in patients with obesity or overweight. The company is clinical-stage, with nimacimab in Phase 2a evaluation. source